Factor VIIa variants

• US 20060019893A1
• Filed: 06/23/2005
• Published: 01/26/2006
• Est. Priority Date: 07/02/2004
• Status: Abandoned Application

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Maun, Henry R., Lazarus, Robert A., Eigenbrot, Charles
• Application Number:
  US11/159,647
• Publication Number:
  US 20060019893A1
• Time in Patent Office: Days
• US Class Current: 530/380
• CPC Class Codes: C12N 9/6437 Coagulation factor VIIa (3.4.21.21)
• CPC Class Codes: C12Y 304/21021 Coagulation factor VIIa (3.4.21.21)

Abstract

Novel compounds are provided which modulate a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention are variants of Factor VIIa (FVIIa). Pharmaceutical compositions are also provided which comprise the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

Claims

1. A Factor VIIa (FVIIa) variant comprising an amino acid sequence derived from a mammalian FVIIa protein, wherein at least two amino acid residues are substituted with a cysteine amino acid.

2. The FVIIa variant of claim 1, wherein the at least two amino acid residues correspond to a human amino acid residue pair selected from the group consisting of S136 and V160, L137 and N159, V138 and V160, S139 and V157, F135 and N159, F135 and P161, V138 and L158, F135 and M156, and, V138 and L155.

3. The FVIIa variant of claim 1, wherein the FVIIa variant comprises an enhanced activity in the absence of tissue factor protein compared to a naturally occurring mammalian FVIIa protein.

4. The FVIIa variant of claim 1, wherein the at least two amino acid residues form a disulfide bond.

5. The FVIIa variant of claim 1, further comprising at least one additional amino acid substitution.

6. The FVIIa variant of claim 5, wherein the at least one additional amino acid substitution contributes to FVIIa variant activity.

7. The FVIIa variant of claim 5, wherein the at least one additional amino acid substitution corresponds to a change in the human amino acid residue selected from the group consisting of E17 (E154), V21 (V158), F135 (F278), S136 (S279), L137 (L280), V138 (V281), S139 (S282), E154 (E296), L155 (L297), M156 (M298), V157 (V299), L158 (L300), N159 (N301), V160 (V302), L163 (L305), M164 (M306), D167 (D309), S170b (S314), K188 (K337), and F225 (F374).

8. The FVIIa variant of claim 7, wherein the change in the human amino acid residue is selected from the group consisting of:

V21D (V158D), V21E (V158E), V21N (V158N), E154V (E296V), E154I (E296I), E154R (E296R), M156Q (M298Q), M156K (M298K), L163V (L305V), M164D (M306D), D167S (D309S), S170bE (S314E), K188A (K337A), and F225Y (F374Y).

9. The FVIIa variant of claim 1, further comprising two or more additional amino acid substitutions.

10. The FVIIa variant of claim 1, wherein the mammalian FVIIa protein is a human FVIIa protein.

19. A composition comprising a pharmaceutically acceptable excipient and the FVIIa variant of claim 1, 11, 15, 16, 17 or 18.

20. A method of altering procoagulation in a mammal comprising administering an effective amount of the composition of claim 19 to the mammal.

21. The method of claim 20, wherein the mammal is a human.

22. The method of claim 20, wherein the alteration is an induction of procoagulation.

23. An isolated DNA molecule encoding the FVIIa variant of claim 1, 11, 15, 16, 17 or 18.

24. The DNA molecule of claim 23, further comprising an expression control sequence operably linked to the DNA molecule.

25. An expression vector comprising the DNA molecule of claim 24, wherein the control sequence is recognized by a host cell with the introduced vector.

26. A host cell introduced with the vector of claim 25.

27. A method of producing a FVIIa variant, the method comprising:

culturing the host cell of claim 26 under condition suitable for expression of the FVIIa variant, thereby producing the FVIIa variant.

28. The method of claim 27, further comprises recovering the FVIIa variant from the culture medium.

11. A Factor VIIa (FVIIa) variant comprising an amino acid sequence derived from a mammalian FVIIa protein, wherein at least two amino acid residues are substituted with an amino acid that locks A2-strand of FVIIa to B2-strand of FVIIa.

12. The FVIIa variant of claim 11, wherein the at least two amino acid residues corresponds to a human amino acid residue pair selected from the group consisting of:

S136 and V160, L137 and N159, V138 and V160, S139 and V157, F135 and N159, F135 and P161, V138 and L158, F135 and M156, and, V138 and L155.

13. The FVIIa variant of claim 11, wherein the amino acid is a cysteine.

14. The FVIIa variant of claim 11, wherein the amino acid is an unnatural amino acid or modified amino acid.

15. A Factor VIIa (FVIIa) variant comprising an amino acid sequence derived from a mammalian FVIIa protein, wherein at least two amino acid residues are substituted with a cysteine amino acid, which correspond to a human amino acid residue pair S136 and V160.

16. A Factor VIIa (FVIIa) variant comprising an amino acid sequence derived from a mammalian FVIIa protein, wherein at least two amino acid residues are substituted with a cysteine amino acid, which correspond to a human amino acid residue pair L137 and N159.

17. A Factor VIIa (FVIIa) variant comprising an amino acid sequence derived from a mammalian FVIIa protein, wherein at least two amino acid residues are substituted with a cysteine amino acid, which correspond to a human amino acid residue pair V138 and V160.

18. A Factor VIIa (FVIIa) variant comprising an amino acid sequence derived from a mammalian FVIIa protein, wherein at least two amino acid residues are substituted with a cysteine amino acid, which correspond to a human amino acid residue pair S139 and V157.